

1 **Title:** Community Led Testing among People Who Inject Drugs: A community centered  
2 model to find new cases of HIV and Hepatitis C in Nepal

3 **Short title:** Community Led HIV and Hepatitis C Testing among People Who Inject Drugs

4 **Authors**

5 Rajesh Didhiya<sup>1</sup>, Tara Nath Pokhrel<sup>2</sup>, Sudha Devkota<sup>2</sup>, Purusotam Raj Shedain<sup>2</sup>, Mukunda  
6 Sharma<sup>4</sup>, Madan Kumar Shrestha<sup>2</sup>, Deepak Gyenwali<sup>1</sup>, Muhammad Imran<sup>4</sup>, Zakir Kadirov<sup>5</sup>,  
7 Bhawani Prasad Dahal<sup>5</sup>, Amrit Bikram Rai<sup>1</sup>, Prawachan Kumar KC<sup>6</sup>, Sabir Ojha<sup>1</sup>, Khem  
8 Narayan Pokhrel<sup>1\*</sup>

9

10 **Author Details**

- 11 1. National Association of People Living with HIV/AIDS in Nepal (NAP+N)
- 12 2. National Centre for AIDS and STD Control (NCASC)
- 13 3. National Public Health Laboratory (NPHL)
- 14 4. Save the Children, US
- 15 5. Save the Children, Nepal Country Office, KPRA Project
- 16 6. SPARSHA Nepal

17

18

19 **\*Corresponding author**

20 Khem Narayan Pokhrel, PhD,  
21 Senior Research Fellow,  
22 National Association of People Living with HIV/AIDS in Nepal (NAP+N),  
23 House NO.: 174, Anek Marg, Baluwatar, Kathmandu-4, Nepal.  
24 Contact phone: +977-01-4427459, 441783.

25 Email: [pratikjee@gmail.com](mailto:pratikjee@gmail.com).

26

27 **Word Count**

28 Abstract:300

29 Main text: 3694

30

## 31 **Abstract**

### 32 **Background**

33 People Who Inject Drugs (PWIDs) have sub-optimal HIV and HCV testing as the available  
34 testing services are inadequate in low and middle-income countries. We examined a model of  
35 Community-Led Testing (CLT) in Nepal, exploring the feasibility of HIV and HCV testing  
36 by trained lay service providers who had similar backgrounds to those of PWIDs. We also  
37 assessed the prevalence of HIV and HCV within this study population and the associated risk  
38 factors among PWIDs.

### 39 **Methods**

40 A mix-method cross-sectional study was conducted among 1029 PWIDs in five major  
41 districts of Nepal from July 2019 to February 2020. Trained PWID peers performed the  
42 screening for HIV and HCV using Rapid Diagnostic Test (RDT) kits. Acceptability and  
43 feasibility of the testing was assessed. The participants' sociodemographic characteristics and  
44 injecting and non-injecting risk characteristics were determined. The association of risk and  
45 prevention characteristics with testing results were assessed using multiple logistic  
46 regression.

### 47 **Results**

48 PWIDs shared that the test providers were friendly and competent in counseling and testing.  
49 Of total PWIDs (n=1,029), 20.6% were HCV-positive and 0.2% were HIV-positive. HCV  
50 positivity was associated with needle sharing (AOR: 1.83, 95% CI: 1.27,2.64; p=0.001) and  
51 reuse of syringe/needle (AOR: 2.26; 95% CI: 1.34, 3.79; p=0.002). In addition, PWIDs were  
52 more likely to be HCV-positive who started opioid substitution therapy (OST) (AOR: 1.88,  
53 95% CI: 1.26, 2.80, p=0.002) and attended the rehabilitation center (AOR: 1.66, 95% CI:  
54 1.10, 2.53, p=0.017).

### 56 **Conclusions**

57 This CLT model was found to be a novel approach of testing of HIV and HCV which was  
58 acceptable to PWIDs in Nepal and showed the high prevalence of HCV and its association  
59 with injecting-related risk behaviors and being users of OST and rehabilitation. The findings  
60 highlight the need of community-led testing in hotspots, OST settings, and rehabilitation  
61 centers to screen new HIV and HCV infections.

62    Keywords: Community-led testing, HIV, HCV, Nepal, People who inject drugs

63

## 64 **Background**

65 People who inject drugs (PWIDs) are a high-risk key population for contracting human  
66 immunodeficiency virus (HIV) and Hepatitis C virus (HCV) infections (1-3). This group  
67 accounts for the major proportion of HCV infections, globally (3). An estimated 2.3 million  
68 people living with HIV are co-infected with HCV globally (3, 4). HCV-induced liver disease  
69 has emerged as a major contributor to mortality and morbidity among people living with HIV  
70 and are co-infected with HCV (5).

71

72 Current HIV and HCV testing services are inadequate in reaching the hard to reach high risk  
73 key populations, particularly PWIDs, which has resulted in the under diagnosis of HIV and  
74 HCV in low-and middle-income countries (LMICs) (6). Such gaps in testing may require  
75 adopting alternative approaches and strategies to achieve the target for elimination of HIV  
76 and hepatitis C as public health threats by 2030 (6, 7).

77

78 Sero-prevalence studies conducted across various sites in Nepal have shown that HCV  
79 prevalence among PWIDs is ranging from 21-38% in men and 3% in women in 2017. The  
80 HIV/HCV co-infection was 2.5 to 7.4% in male PWIDs and 0.6% in female PWIDs  
81 depending upon the study site in the country (8-10). Although Nepal has made progress in  
82 improving accessibility of testing and treatment of HIV, an estimated 22% of the HIV-  
83 positive people remain undiagnosed (11). In addition, HCV testing services are only available  
84 in clinic-based settings, and PWIDs may not feel comfortable to seeking these testing  
85 services from the facilities. PWIDs also face social and environmental challenges such as  
86 poverty, homelessness, criminalization of drug injecting, lack of confidentiality, stigma, and  
87 discrimination (12, 13).

88

89 In order to overcome the prevailing barriers and bridge the gap in testing of HIV and HCV,  
90 an innovative model of Community-Led Testing (CLT) was conceived, developed, and tested  
91 in Nepal. In this model, trained In-reach Workers (IRWs) who had similar backgrounds to  
92 those of PWIDs performed HIV and HCV screening using easy to use rapid diagnostic test  
93 kits (RDTs) in the community, bringing testing services closer to those most at risk and who  
94 might not otherwise have been tested (14). IRWs are the peer educators and lay service  
95 providers to PWIDs who engaged in community service organizations (CSOs) in Nepal.  
96 Community led or community driven approaches have increased acceptability and

97 effectiveness of the interventions employed to improve access to HIV services in some  
98 African countries (15-17). Such a community-led model was also found to be effective in  
99 overcoming barriers and reaching the hard to reach, vulnerable and stigmatized key  
100 populations in HIV testing in Vietnam, and community home-based care support has  
101 improved ART adherence in Nepal as well (18, 19). CLT model for HIV screening has been  
102 implemented in Nepal since 2018. However, its acceptability and effectiveness is yet to be  
103 examined (14). Moreover, there are no PWIDs focused HCV screening programs in  
104 community settings.

105

106 This study aimed to examine the acceptability and feasibility of a CLT model of testing for  
107 HIV and HCV among PWIDs and linking PWIDs to the available treatment, care, and support  
108 services. In addition, we assessed the prevalence of HIV, HCV, HIV/HCV co-infection and  
109 the associated risk factors with HCV.

110

## 111 **Materials and Methods**

### 112 *Study design*

113 A mix-methods cross-sectional CLT study was designed and conducted among PWIDs in  
114 five major districts of Nepal. The qualitative approach explored in-depth knowledge on  
115 acceptability and feasibility of this CLT model from clients' and providers' perspectives.  
116 While the quantitative approach was used to examine the risk characteristics of PWIDs and to  
117 measure the prevalence of HIV and HCV, the study spanned from July 2019 to February  
118 2020.

### 119 *Study setting, sample size and sampling strategy*

120 We purposively selected five districts where an estimated 30% of all PWIDs in Nepal reside  
121 (18). Calculation of sample size was based on the current highest prevalence of HCV at 38%  
122 according to the integrated biological and behavioural survey (IBBS) conducted in Nepal (9).  
123 Sample size was calculated using G\*Power 3.1.9.6 for macOS, employing the 95%  
124 confidence interval and 80% power, the calculated sample size was 980. In addition to taking  
125 the reference prevalence of HCV, injecting related characteristics and their association with  
126 HCV positivity might need to be considered. Therefore, we increased the sample size to  
127 1,029. We applied convenience sampling methods to reach the PWIDs peers through IRWs.

128 ***Data Collection***

129 Participants were recruited from satellite sites covering hot spots (e.g., the location or secret  
130 places where PWIDs generally meet to inject drugs), drop-in centres (DIC), needle/syringe  
131 exchange program locations, opioid substitution therapy (OST) sites, and rehabilitation  
132 centres. IRWs of the district-based CSOs were trained with five-days intensive training  
133 package for conducting CLTs, counselling, and data collection including the practices on  
134 KOBO data collection platform using Android tablets (20). Geographical tracking was also  
135 done to trace location of the participants from the office to the site where they were  
136 interviewed. Trained IRWs and peers were mobilized to identify and contact the participants.

137 For qualitative data collection in-depth interviews (IDIs) were conducted among 70  
138 participants from five study districts who were enrolled in CLT for screening HIV and HCV.  
139 Similarly, three Focus Group Discussions (FGDs) were conducted in three project sites  
140 among key CLT service providers covering IRWs, lab personnel, and counsellors. Trained  
141 professionals were mobilized to conduct IDIs and FGD sessions. Validated IDIs and FGD  
142 topic guides were used in the study.

143 ***Participant inclusion criteria***

144 PWIDs were considered eligible for the study if they were current or past injecting drug users  
145 who, had injected drugs for at least 3 months before they were recruited in the study, and had  
146 never tested or tested negative for HIV and /or HCV within the 12 months preceding the  
147 survey. Participants aged 16 years and above were enrolled. All the participants meeting  
148 inclusion criteria had provided consent to enrol in the study and to provide information.  
149 Therefore, no participants from the sample were excluded in the study.

150 ***Study variables***

151 **Socio-demographic information:** Participants' age, ethnicity, educational status, marital  
152 status, gender, and occupation, history of HIV and HCV testing were recorded adopting the  
153 survey instruments of the Nepal Demographic Health Survey, 2016 (21).

154 **Injection related risk characteristics:** We adopted the questionnaires about the injection  
155 related risk characteristics covering needle sharing behaviors and other equipment sharing as  
156 defined by the IBBS study in Nepal (8, 9).

157 **HIV and HCV risk factors:** The risk factors were adopted from the Nepal IBBS study  
158 covering tattoos or body piercing, having sexual partner with status of HIV or with chronic  
159 hepatitis C/HIV, condom use, and weekly alcohol use (9).

160 **Prevention activities:** We interviewed the participants about their exposure to peer-  
161 education interventions, opioid substitution therapy, rehabilitation, needle and syringe  
162 exchange programs following the harm reduction programs activities of National Center for  
163 AIDS and STDs Control (NCASC).

164 **Biological test:** HCV and HIV screening used RDTs. Alere Determine™ HIV-1/2 and SD  
165 BIOLINE HCV RDTs were used for screening HIV and HCV, respectively, using blood  
166 samples from finger pricks in the satellite sites covering various hotspots, OST clinics,  
167 drop-in centers, and rehabilitation centers. Trained and certified IRWs performed screening  
168 of HIV and HCV of PWIDs and recorded clients' information including behavioural  
169 characteristics and test results in client report form (CRF) at satellite sites.

170 **Qualitative information:** Qualitative data collection methods such as FGDs and IDIs were  
171 applied to test the thematic topics: acceptability, feasibility, challenges/bottlenecks and  
172 unplanned effect of CLT.

173 Figure 1 Algorithm : The HIV/HCV CLT model in Nepal (See attached image)

174

175

176

177

178

179

180

181

182

183

184

185

Figure 1: The HIV/HCV CLT model in Nepal



186 ***Data analysis***

187 Quantitative data were analyzed using STATA version 14.0. Descriptive analyses were done  
188 covering client's characteristics and the prevalence of HIV, HCV and HIV/HCV co-infection  
189 stratified by gender. Logistic regression analysis was applied to identify the association of  
190 socio-demographic characteristic and risk related characteristics with the prevalence of HCV.  
191 Results of HIV testing precluded meaningful analyses, since the number was so low.

192 The qualitative interviews and focus groups were transcribed and translated into English. The  
193 contents of transcripts were analyzed based on the pre-defined and emerging themes and sub-  
194 themes. We used MAXQDA 2020 (22) software for data coding, data sorting and extracting  
195 quotes according to theme.

196 ***Ethical consideration***

197 As PWIDs are vulnerable, socially stigmatized and criminalized for drug use in Nepal, the  
198 study was conducted maintaining optimal ethical and human rights standards throughout the  
199 study period. Written informed consent was taken from all the participants before enrolling  
200 them in the study. Similarly, written assent was taken from senior peers of the participants  
201 below 18 years of age. Ethical approval was obtained from ethical review board of the Nepal  
202 Health Research Council (NHRC) [**Reg No. 552/2019**] prior to the commencement of the  
203 fieldwork.

204

205 Participants, who tested as HIV and HCV negative were counselled on safer behaviors and  
206 referred to harm reduction programs. Participants identified as either HIV and/or HCV  
207 positive were referred to the demonstration sites for counseling, HIV confirmatory test,  
208 linkages for HIV treatment, care and support, and to collect blood sample for HCV  
209 RNA/PCR. Participants identified as HCV positive were linked to post-test counselling  
210 services, liver fibrosis assessment through APRI scoring and referred to a hepatologist for  
211 appropriate follow up.

212

213

214

215

## 216 **Results**

### 217 **Sociodemographic characteristics of Participants**

218 Of total participants (n=1,029), 91.6% were men and 8.4% were women. Mean ages were  
219 28.6 (SD=7.0) years for men and 23.4 (SD=3.7) years for women. Proportion of women in  
220 the age group of 16-24 years was 66.3% and that of men was 34.3%. The majority of  
221 participants were Janajati (Disadvantaged Janajati: 26.3% and Advantaged Janajati: 35.6%).  
222 About 63.1% of men and 75.6% of women were unmarried. Nearly two thirds (61.7%) of the  
223 participants were unemployed. Those who had ever enrolled in school, their mean year of  
224 schooling was 9.8 (SD=2.4) (Table 1).

### 225 **Risk related characteristics of participants by gender**

226 Of total (n=1029), 56.8% were current drug users. More than half (51.6%) of the participants  
227 reported that they had never tested for HIV. Regarding risk behaviors, 75.0% reported that  
228 they reused needles, 50.5% shared needles/syringes, and 29.9% shared a  
229 cooker/vial/container. About 55% of the participants were recruited from hotspots and 29%  
230 were from rehabilitation centers.

231 About 61.0% of the participants had an injection history of more than five years, and 43.6%  
232 reported that they had injected in the last seven days. Regarding needle/syringe sharing, 50%  
233 of men and 57.0% of women reported that they shared needles. In addition, 29.9% of  
234 participants reported that they had a practice of sharing a cooker/vial/container. Regarding  
235 other risk characteristics, 30.4% of men and 5.8% of the women consumed alcohol weekly,  
236 and 57.0% of the total participants had done tattooing. Nearly half of the women (47.7%)  
237 responded that they did not know their partner's HIV status, and 37.5% of men did not know  
238 their partner's status. While having sex with regular partner/sex workers, 57.1% reported that  
239 they always used condoms (Table 2).

### 240 **Past testing, prevention exposure according to gender**

241 Of the total, 17% of the participants reported that they had HCV test at least 12 months prior  
242 to the survey. Regarding the reason for not testing for HCV, 43.0 % reported fear of  
243 confidentiality breaches and 39.5% were not aware of the risk of HCV and HIV. Other  
244 reasons were screening is too expensive (23.5%), carelessness within themselves (18.0%),  
245 and no treatment is available (11.5%). About 10.5% reported that they did not know the  
246 testing facilities. About 52.9% of men and 62.8% of women participated in the IRW provided

247 harm reduction intervention, 28.1% started OST, and 63.2% attended a rehabilitation center.  
248 About 69.6% reported that they had participated in needle/syringe exchange program. About  
249 61.8% reported that they felt stigma from family; a higher proportion of men compared to  
250 women (63.7% vs. 40.7%) felt stigma from family.

251 The overall prevalence of HCV in this sample was 20.6% (men=21.2%; women=14.0%). All  
252 HCV-positive participants were referred to demonstration sites to collect blood samples and  
253 the samples were sent to the National Public Health Laboratory [NPHL] for HCV RNA/PCR  
254 test. Only two men (0.2%) tested HIV positive and had HCV positive test as well. HIV-  
255 positive samples were sent for confirmatory tests using three RDTs as per national HIV  
256 testing algorithm. Both participants were confirmed as HIV positive, and both were linked to  
257 ART services. Among those who tested for HCV RNA (n=203), 68% had HCV RNA (IU/ml)  
258 count ranging from 65 to 1000000 (Table 3).

#### 259 **Descriptive analysis of socio-demographic and risk characteristics and their association** 260 **with HCV screening result**

261 Significantly higher proportion of participants in the age group of 25-50 years were HCV  
262 positive (77.4%) compared with those in the age group of 16-24 years and above 50 years  
263 ( $p<0.001$ ). A higher proportion of married participants were HCV positive (57.1%)  
264 compared to unmarried and divorced/separated participants ( $p<0.001$ ). HCV negative  
265 participants had a higher mean number of years of schooling than HCV positive [negative  
266 mean=10.1 (SD=2.2) vs. positive: mean=8.9 (SD=2.7),  $p<0.001$ ].

267 A higher proportion of participants who reported needle sharing (58.0%) were HCV positive  
268 compared to those who did not share needles ( $p=0.014$ ). In addition, a higher proportion  
269 participant who shared a cooker/vial/container were HCV positive compared to those who  
270 did not share (positive: 37.3% vs. negative: 28.0%,  $p=0.009$ ). In addition, there was a  
271 significant difference on HCV positive and HCV negative results between those who  
272 reported re-use of needle/syringe compared with who did not reuse needle and syringes.  
273 (positive: 86.2% vs. negative: 72.1%,  $p<0.001$ ).

274 Regarding risky sexual behaviors, those participants who had sexual contact with a person of  
275 unknown HIV status had higher proportion of HCV positive results (positive: 30.2% vs.  
276 negative: 20.3%,  $p=0.002$ ) compared with participants who had no sexual contact or knew  
277 the HIV status of their partner. Those participants who always used condoms had a low  
278 proportion of HCV positive results compared to those who did not use condoms and used

279 them only sometimes (positive: 37.4% vs. negative: 50.6%,  $p=0.001$ ). Also, PWIDs with  
280 tattoos had a higher prevalence of HCV positive than those without tattoos(positive: 67.5%  
281 vs. negative: 54.2%,  $p<0.001$ ). Similarly, participants who consumed alcohol weekly had a  
282 higher proportion of HCV positive results relative to those who did not consume alcohol  
283 weekly (positive: 75.9% vs. negative: 67.9%,  $p=0.024$ ). (Table 4).

#### 284 **Descriptive analysis of risk behavior and prevention exposure associated with HCV** 285 **screening result**

286 A higher proportion of HCV positive PWIDs had started OST compared to HCV negative  
287 (positive: 46.2% vs. negative: 23.4%,  $p<0.001$ ). Rehabilitation participants had a higher  
288 proportion of HCV positive test results (positive: 76.4% vs. negative: 59.7%,  $p<0.001$ )  
289 relative to non-participants, and a higher proportion of HCV positive results were found  
290 among subjects who were involved in needle/syringe exchange programs (positive: 75.9% vs.  
291 negative: 67.9%,  $p=0.024$ ). (Table 5).

#### 292 **Multivariate analysis of injecting risk behavior, prevention exposure associated with** 293 **HCV screening results**

294 Analyses were performed controlling for age, sex, marital, education level, tattooing, and  
295 participation in a needle/ syringe exchange program. Higher odds of HCV positive results  
296 were found in participants who had practice of needle sharing (AOR: 1.83, 95% CI:  
297 1.27,2.64,  $p=0.001$ ) and reuse of syringes/needles (AOR: 2.26, 95% CI: 1.34, 3.79,  $p=0.002$ ).  
298 In addition, HCV positive results were positively associated with those who started OST  
299 (AOR: 1.88, 95% CI: 1.26, 2.80,  $p=0.002$ ) and attended a rehabilitation center (AOR: 1.66,  
300 95% CI: 1.10, 2.53,  $p=0.017$ .) (Table 6).

#### 301 **Qualitative findings**

##### 302 *Feasibility of CLT*

303 IRWs shared their experience  
304 and perceptions about the  
305 feasibility of community led  
306 testing. Doing RDT was  
307 convenient for them because  
308 they found that PWIDs were

*“I never thought that I would have this much skills in counseling and testing. The training made me more skilled in testing procedures. I felt myself proud to reach my peer PWIDs who never get tested. It is really the rewarding job testing by the community for the community” ---20’s IRW*

309 ready to get tested and agreed to

310 tested by their peers. They shared the positive and encouraging aspect of this model was

be

311 “testing by the community for the community.” The trained IRWs shared that they developed  
312 confidence as they had proper skill for procedure through the training and having received a  
313 certificate from a government authority. Another aspect shared by the trained peer was that  
314 they felt empowered and employed to test their community for the benefit of the community.  
315 The testing was easier for them as they found willingness among the peer PWIDs to get  
316 tested and refer their friends for testing for HIV and HCV.

317

### 318 ***Acceptability of CLT***

319 The community led testing was acceptable among the participants as they reported that they  
320 found friendly behavior among test providers and perceived that the trained test providers had  
321 competence in counseling and testing. In addition, participants reported that they  
322 were happy to have immediate test results and having the testing place of  
323 their choice. Regarding privacy and confidentiality, PWIDs felt assured about the privacy maintained by the IRWs for testing.  
324 They had also greater trust toward the interviewers and test takers in the field. They had trust  
325 on pre-counseling and testing, and felt that their community are the service provider for the  
326 benefit of their diagnosis. Their perception was that they received exceptional support from  
327 their peers in testing and counseling from trained IRWs.

*“I felt praised to meet my friend in the usual injecting site. Got very much impressed with his pre-test counseling and his confidence in testing procedure. Relieved to have result instantly”. - 30’s PWID*

331

### 332 ***Bottlenecks/challenges***

333 A few IRWs perceived that it was difficult for them in  
334 finding PWIDs who have not tested. Another problem that  
335 the trained peer said that in some cases they had difficulty

*“I don’t know how we could overcome the interference of police as our protocol says we can test in the hotspots. I never discouraged from the incident of some sites as we encountered the police during testing. I kept on testing as I felt it is helping to the community” ---20’s IRW*

339 in finding a private testing venue because some were feeling uncomfortable because police  
340 might interfere- as drug use is treated as a criminal act in Nepal. However, they never got  
341 discouraged and kept on going for testing and finding the community. Some thought that they  
342 had problems convincing the peers about the treatment available for HCV infection if they

343 tested positive. However, they referred positive participants for the consultation with the  
344 hepatologist.

## 345 **Discussion**

346 This study is the novel of its kind in Nepal, which applied CLT model to screen the hidden  
347 PWIDs affected by HIV and HCV. The model was proven a feasible testing approach for  
348 HIV and HCV in a low-resource setting such as Nepal and was acceptable by PWIDs. The  
349 lay test providers and peers/IRWs had confidence in reaching, providing counseling,  
350 maintaining the privacy of PWIDs and testing in the satellite sites. The test providers also felt  
351 empowered as they were doing something for their own community: “Testing by the  
352 community for the community”. Although a few service providers had some difficulties in  
353 finding private testing locations and felt fear of interference from the police, they were able  
354 to reach the PWIDs in convenient places and provide testing upon request. In addition,  
355 PWIDs shared that the test providers were friendly and were competent in counseling and  
356 testing. They shared that the best part of the CLT was that they received the result instantly  
357 and were referred for further services. This model can be one of the approaches to overcome  
358 the access barriers for PWIDs for seeking services from clinical settings (13, 18, 23).

359 This study found that 0.2% of participants had HIV and 20% had HCV. The lower rate of  
360 HIV could be due to better utilization of testing services and their exposure to prevention  
361 services. Also, those who had HIV testing prior to 12 months of the survey were not included  
362 in this model. The reliability of testing was promising as the result accuracy was 100% while  
363 performing confirmatory testing in National Public Health Laboratory (NPHL).

364 HCV positivity result is in line with the IBBS study findings, which has shown the  
365 prevalence ranging from 18.8 to 38% (8-10). The true prevalence of HCV among PWIDs  
366 could be even higher than that revealed by the study if the criteria "never tested or tested  
367 HCV negative at least for last 12 months" were not used. This statement is supported by the  
368 findings of a study conducted in 2015 which had shown almost 50% of the PWIDs with  
369 HCV-RNA sought services from organized institutions (24).

370 PWIDs represent 3% of the total cases of HIV in Nepal and HIV incidence was 0.03% in  
371 2020 and the prevalence among adult population was 0.13% (11). The study results indicated  
372 that PWIDs who were not reached by the ongoing program for HIV screening and could be  
373 reached through this peer-led approach (16, 18) although detection of HIV is fairly low. This

374 CLT approach would be complementary to the current HIV/HCV screening services, as the  
375 PWIDs feel stigma and fear of confidentiality breaches in the health facilities that have  
376 resulted in non-availability or inaccessibility of the screening services (13, 18, 23).

377 This study also found that needle sharing and needle reuse were major risk factors for HCV  
378 infection. Reuse of needles and needle/ syringe sharing may have increased the risk of  
379 vulnerability of transmission. In addition, HCV positivity rate was found to be high among  
380 PWIDs who started their OST and attended rehabilitation center. Participants seeking  
381 services from institutions may have history of years of injecting drug use before enrollment  
382 in the services and might have not used the available testing for HCV services with a fear of  
383 lack of treatment availability of HCV. Longer duration of exposure is positively associated  
384 with HCV infection and the longer duration increases the repeated high risk behaviors such  
385 as needle sharing, re-use of needles, and unsafe sexual behaviors (24, 25).

386 Despite the major significance of this CLT model, the study has two major limitations. First,  
387 due to nature of screening hidden PWIDs, we applied non-probability sampling led by peer  
388 PWIDs. This may affect the generalizability of the results. However, IRWs were reaching  
389 every satellite site with the mapping so that they would be able to reach more hidden and  
390 non-diagnosed cases. Second, we were not able to assess the factors associated with HIV-  
391 positivity because of the low prevalence in the screened populations. However, the risk  
392 characteristics of HCV and HIV could be assumed similar such as needle sharing and sharing  
393 of injecting preparation materials.

#### 394 **Conclusion:**

395 This CLT study has shown that peer lay test providers were well accepted by PWIDs for  
396 counseling and testing. This model has become promising to test for HCV and HIV among  
397 PWIDs in their convenient sites. Also, the study shows that risk behaviour such as needle re-  
398 use and needle sharing led to HCV infection. Moreover, higher proportion of PWIDs in  
399 rehabilitation center and on OST were also tested positive for HCV. Therefore, this study  
400 highlights the expansion of this model to screen for both HCV and HIV together in other  
401 parts of the country and similar settings, where PWIDs encounter barriers to access to testing  
402 services.

403  
404  
405

406 **Acknowledgments**

407

408 We acknowledge the CSOs involved in this research project SPARSHA Nepal-Kathmandu,  
409 Community Support Group-Kaski, and Nirmaya-Chitwan. We would like to thank the IRWs,  
410 who successfully conducted the testing and field work for quantitative data collection and  
411 qualitative researchers who conducted IDIs and FGDs. We owe to all 1029 PWIDs who  
412 successfully and willingly participated in this study, provided information, agreed for the test  
413 of HIV and HCV in the satellite places. We have also number of consultants to acknowledge  
414 who provided the inputs in design. Further, we would like to acknowledge the support  
415 received from the administrative, logistic, and financial staffs of Save the children, NCASC,  
416 NAP+N, and NPHL.

417

418

419 **Author Contributions**

420

421 **Conceptualization:** Rajesh Didiya, Tara Nath Pokhrel, Zakir Kadirov, Purusotam Raj Sedai,  
422 Mukunda Sharma, Madan Kumar Shrestha, Deepak Gyenwali, Bhawani Prasad Dahal, Amrit  
423 Bikram Rai, Khem Narayan Pokhrel

424 **Data curation:** Deepak Gyenwali, Khem Narayan Pokhrel

425 **Formal analysis:** Khem Narayan Pokhrel, Deepak Gyenwali

426 **Supervision:** Rajesh Didiya, Deepak Gyenwali, Tara Nath Pokhrel, Khem Narayan Pokhrel

427 **Validation:**Tara Nath Pokhrel, Bhawani Prasad Dahal, Zakir Kadirov, Khem Narayan  
428 Pokhrel

429 **Manuscript preparation and finalization:** Khem Narayan Pokhrel

430 **Manuscript – review & editing:** Rajesh Didiya, Tara Nath Pokhrel, Zakir Kadirov,  
431 Muhammad Imran, Purusotam Raj Sedai, Mukunda Sharma, Madan Kumar Shrestha, Deepak  
432 Gyenwali, Bhawani Prasad Dahal, Amrit Bikram Rai, Sabir Ojha, Prawachan Kumar KC

433

434

435

436

437



## 438 **References**

- 439 1. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global  
440 prevalence of injecting drug use and sociodemographic characteristics and prevalence of  
441 HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. *The*  
442 *Lancet Global Health*. 2017;5(12):e1192-e207.
- 443 2. Rashti R, Alavian SM, Moradi Y, Sharafi H, Bolbanabad AM, Roshani D, et al. Global  
444 prevalence of HCV and/or HBV coinfections among people who inject drugs and female  
445 sex workers who live with HIV/AIDS: a systematic review and meta-analysis. *Archives*  
446 *of Virology*. 2020:1-12.
- 447 3. WHO. Global hepatitis report 2017: World Health Organization 2017. Report No.:  
448 9241565454.
- 449 4. WHO. HIV/AIDS Key facts. 2018:1-7. Available from [https://www.who.int/news-](https://www.who.int/news-room/fact-sheets/detail/hiv-aids)  
450 [room/fact-sheets/detail/hiv-aids](https://www.who.int/news-room/fact-sheets/detail/hiv-aids). Accessed on September 16, 2020.
- 451 5. Poudel KC, Palmer PH, Jimba M, Mizoue T, Kobayashi J, Poudel-Tandukar K.  
452 Coinfection with hepatitis C virus among HIV-positive people in the Kathmandu Valley,  
453 Nepal. *Journal of the International Association of Providers of AIDS Care (JIAPAC)*.  
454 2014;13(3):277-83.
- 455 6. WHO. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral  
456 hepatitis: World Health Organization. 2016.
- 457 7. WHO. Global health sector strategy on HIV 2016-2021. Towards ending AIDS: World  
458 Health Organization. 2016.
- 459 8. NCASC. Integrated Biological and Behavioral Surveillance ( IBBS ) Survey among  
460 People Who Inject Drugs ( PWID ) in Kathmandu Valley. Kathmandu Nepal.  
461 Kathmandu, Nepal. 2017.
- 462 9. NCASC. Integrated Biological and Behavioural Surveillance (IBBS) Surveys among  
463 People Who Inject Drugs (PWID) in Eastern Terai Highway Districts. Kathmandu,  
464 Nepal: National Center for AIDS and STDs Control. 2017.
- 465 10. NCASC. Integrated Biological and Behavioural Surveillance (IBBS) Surveys among  
466 People Who Inject Drugs (PWID-Male) in Pokhara Valley: National Center for AIDS  
467 and STDs Control. 2017.
- 468 11. HIV Epidemic Update of Nepal [database on the Internet]2020 [cited 12.15.2020].  
469 Available from: <http://www.ncasc.gov.np/WAD2020/Factsheet-2020-S.pdf>.

- 470 12. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global  
471 epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of  
472 systematic reviews. *The Lancet*. 2011;378(9791):571-83.
- 473 13. Barocas JA, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Barriers and  
474 facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-  
475 methods study. *Harm reduction journal*. 2014;11(1):1-8.
- 476 14. NCASC. National Guidelines Community-Led HIV Testing 2017 Nepal. Kathmandu  
477 Nepal: National Center for AIDS and STDs Control; 2017.
- 478 15. Ndyomugenyi R, Kabali AT. Community-directed interventions for integrated delivery  
479 of a health package against major health problems in rural Uganda: perceptions on the  
480 strategy and its effectiveness. *International health*. 2010;2(3):197-205.
- 481 16. Indravudh PP, Fielding K, Kumwenda MK, Nzawa R, Chilongosi R, Desmond N, et al.  
482 Community-led delivery of HIV self-testing to improve HIV testing, ART initiation and  
483 broader social outcomes in rural Malawi: study protocol for a cluster-randomised trial.  
484 *BMC infectious diseases*. 2019;19(1):814.
- 485 17. Sharma M, Barnabas RV, Celum C. Community-based strategies to strengthen men's  
486 engagement in the HIV care cascade in sub-Saharan Africa. *PLoS medicine*.  
487 2017;14(4):e1002262.
- 488 18. Nguyen VTT, Phan HT, Kato M, Nguyen QT, Le Ai KA, Vo SH, et al. Community-led  
489 HIV testing services including HIV self-testing and assisted partner notification  
490 services in Vietnam: lessons from a pilot study in a concentrated epidemic setting.  
491 *Journal of the International AIDS Society*. 2019;22:e25301.
- 492 19. Pokhrel KN, Sharma VD, Pokhrel KG, Neupane SR, Mlunde LB, Poudel KC, et al.  
493 Investigating the impact of a community home-based care on mental health and anti-  
494 retroviral therapy adherence in people living with HIV in Nepal: a community  
495 intervention study. *BMC infectious diseases*. 2018;18(1):263.
- 496 20. KoboToolbox. *KOBO Tool Box* Cambridge, MA: The Harvard Humanitarian Initiative; 2019 [cited  
497 2021 10.11.2020]; Available from: <https://www.kobotoolbox.org/>.
- 498 21. MOHP Nepal. *Nepal Demographic and Health Survey 2016*. Kathmandu: Ministry of  
499 Health 2017.
- 500 22. Software V. *MAXQDA 2020*. 2019.
- 501 23. Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S, et al. Barriers to and facilitators  
502 of hepatitis C testing, management, and treatment among current and former injecting  
503 drug users: a qualitative exploration. *AIDS patient care and STDs*. 2010;24(12):753-62.

- 504 24. Kinkel H-T, Karmacharya D, Shakya J, Manandhar S, Panthi S, Karmacharya P, et al.  
505 Prevalence of HIV, hepatitis B and C infections and an assessment of HCV-genotypes  
506 and two IL28B SNPs among people who inject drugs in three regions of Nepal. PLoS  
507 One. 2015;10(8).
- 508 25. Poudel KC, Poudel-Tandukar K, Yasuoka J, Joshi AB, Jimba M. Correlates of sharing  
509 injection equipment among male injecting drug users in Kathmandu, Nepal. International  
510 Journal of Drug Policy. 2010;21(6):507-10.
- 511  
512  
513

514 **Tables**

515 **Table 1: Socio-demographic characteristics of participants by gender**

<b>Characteristics</b>	<b>Men (n=943) (n, %)</b>	<b>Women (n=86) (n, %)</b>	<b>Total (n, %)</b>
Age (mean, SD)	28.6 (7.0)	23.4 (3.7)	28.2 (7.0)
<b>Age groups</b>			
16-24 years	323 (34.3)	57 (66.3)	380 (36.9)
25-50 years	610 (64.7)	29 (33.7)	639 (62.1)
Above 50 years	10 (1.0)	0 (0.0)	10 (1.0)
<b>Ethnicity</b>			
Dalit	81 (8.6)	8 (9.4)	89 (8.7)
Disadvantaged Janajati	245 (26.0)	25 (29.0)	270 (26.3)
Disadvantaged non-Dalit Terai	2 (0.2)	1 (1.2)	3 (0.3)
Religious minorities (Muslim)	8 (0.9)	0 (0.0)	8 (0.8)
Advantaged Janajati	340 (36.1)	26 (30.2)	366 (35.6)
Upper caste (Brahmin/Chhetri)	266 (28.2)	26 (30.2)	292 (28.3)
<b>Marital status</b>			
Unmarried	595 (63.1)	65 (75.6)	660 (64.1)
Married	339 (36.0)	21 (24.4)	360 (35.0)
Divorced/separated	9 (1.0)	0 (0.0)	9 (0.9)
<b>Occupation</b>			
Unemployed	562 (59.6)	73 (84.9)	635 (61.7)
Professional/technical/Managerial	7 (0.7)	0 (0.0)	7 (0.7)
Labor	96 (10.2)	2 (2.3)	98 (9.5)
Business	134 (14.2)	6 (7.0)	140 (13.6)
Agriculture	8 (0.9)	0 (0.0)	8 (0.8)
Student	52 (5.5)	3 (3.5)	55 (5.3)
Others	84 (8.9)	2 (2.3)	86 (8.4)
<b>Education level</b>			
Illiterate	0 (0.0)	8 (0.9)	8 (0.8)
Literate but not formal education	12 (1.3)	4 (4.7)	16 (1.6)
Formal education received	923 (97.9)	82 (95.4)	1005 (97.7)
<b>Mean (SD) schooling years (n=1005)</b>	9.4 (2.4)	9.8 (2.4)	9.8 (2.4)

516

517 **Table 2: Risk characteristics of participants by gender**

<b>Characteristics</b>	<b>Men (n=943, %)</b>	<b>Women (n=86, %)</b>	<b>Total (n=1029, %)</b>
<b>Ever drug use</b>			
Current	531 (56.3)	54 (62.8)	585 (56.8)
Past	412 (43.7)	32 (37.2)	444 (43.2)
<b>Last test of HIV Done</b>			
Never	490 (52.0)	41 (47.7)	531 (51.6)
Before 12 months	453 (48.0)	45 (52.3)	498 (48.4)
<b>Risk behavior (multiple response)</b>			

Shared a needle	471 (50.0)	49 (57.0)	520 (50.5)
Shared a cooker/vial/container	288 (30.5)	20 (23.3)	308 (29.9)
Shared a cotton/filter/rinse water	43 (4.6)	1 (1.2)	44 (4.3)
Re-used syringe/needle	717 (76.0)	55 (64.0)	772 (75.0)
Not shared	30 (3.2)	0 (0.0)	30 (2.9)
<b>Type of satellite</b>			
DIC	33 (3.5)	1 (1.2)	34 (3.3)
Hotspots	516 (54.7)	50 (58.1)	566 (55.0)
OST Clinic	71 (7.5)	2 (2.3)	73 (7.1)
Rehabilitation center	272 (28.8)	31 (36.1)	303 (29.5)
ART Clinic	2 (0.2)	0 (0.0)	2 (0.2)
Others	49 (5.2)	2 (2.3)	51 (5.0)
<b>Injecting duration</b>			
<=1 year	25 (2.7)	7 (8.1)	32 (3.1)
Between one year and five years	323 (34.3)	46 (53.5)	369 (35.9)
More than five years	595 (63.1)	33 (38.4)	628 (61.0)
<b>Last injected (days)</b>			
<=7 days	417 (44.2)	32 (37.2)	449 (43.6)
8-30 days	109 (11.6)	22 (22.6)	131 (12.7)
31 days or more	417 (44.2)	32 (37.2)	449 (43.7)
<b>Weekly alcohol use</b>			
Yes	287 (30.4)	5 (5.8)	292 (28.3)
No	656 (69.6)	81 (94.2)	737 (71.6)
<b>Tattoo</b>			
Yes	546 (57.9)	40 (46.5)	586 (57.0)
No	397 (42.1)	46 (53.5)	443 (43.0)
<b>Partner status</b>			
HIV-positive	2 (0.2)	0 (0.0)	2 (0.2)
Hepatitis C	2 (0.2)	1 (1.2)	3 (0.3)
Don't know	354 (37.5)	41 (47.7)	395 (38.4)
None	585 (62.0)	44 (51.2)	629 (61.1)
<b>Condom use with casual partners/SWs</b>			
Never			51 (5.0)
Always			588 (57.1)
Sometimes			326 (31.7)
Never had sex with SWs			64 (6.2)

518 **Table 3: Past testing, prevention, stigma, and current testing results by gender**

Characteristics	Men (n=943,%)	Women (n=86,%)	Total (n=1029)
<b>Past HCV test</b>			
Yes	170 (18.0)	5 (5.8)	175 (17.0)
No	773 (82.0)	81 (94.2)	854 (83.0)
<b>Reason for not testing HCV (multiple response)</b>			
Not aware of the risk	299 (38.6)	41 (50.6)	340 (39.7)
Don't know about the testing	87 (11.2)	3 (3.7)	90 (10.5)

facilities			
Testing facility is too far	18 (2.3)	1 (1.2)	19 (2.2)
Fear of stigma in the facility	60 (7.7)	5 (6.2)	65 (7.6)
Fear of confidentiality	338 (43.6)	30 (37.0)	368 (43.0)
Screening is too expensive	189 (24.4)	12 (14.8)	201 (23.5)
No treatment is available	92 (11.9)	6 (7.4)	98 (11.5)
Carelessness	148 (10.7)	6 (0.7)	154 (18.0)
<b>Participated in IRW intervention</b>			
Yes	499 (52.9)	54 (62.8)	553 (53.7)
No	444 (47.1)	32 (37.2)	476 (46.3)
<b>OST started</b>			
Yes	278 (29.5)	11 (12.8)	289 (28.1)
No	664 (70.5)	75 (87.2)	739 (71.9)
<b>Attended in Rehabilitation center</b>			
Yes	600 (63.6)	50 (58.1)	650 (63.2)
No	343 (36.8)	36 (41.9)	379 (36.8)
<b>Participated in needle/syringe exchange program</b>			
Yes	653 (69.3)	63 (73.2)	716 (69.6)
No	290 (30.8)	23 (26.7)	313 (30.4)
<b>Stigma</b>			
Stigma from family	601 (63.7)	35 (40.7)	636 (61.8)
Stigma in the health facility	64 (6.8)	1 (1.2)	65 (6.3)
Stigma in office/work	42 (4.5)	0 (0.0)	42 (4.1)
Not felt stigma	325 (34.5)	51 (59.3)	376 (36.5)
Stigma felt in other places	38 (4.0)	1 (1.2)	39 (3.8)
<b>HCV screening result</b>			
Positive	200 (21.2)	12 (14.0)	212 (20.6)
Negative	743 (78.8)	74 (86.0)	817 (79.4)
<b>HIV screening result</b>			
Positive	2 (0.2)	0(0.0)	2 (0.2)
Negative	941 (99.8)	86 (100.0)	1027 (99.8)
<b>HIV confirmatory test 3RDT proposed (yes)[as per national HIV testing algorithm]</b>	2 (100.0)	0 (0.0)	2 (100.0)
<b>HCV RNA (IU/ml) (n=203)</b>			
<65			61 (30.0)
65 to 1000000			138 (68.0)
>1000000			4 (2.0)

519 **Table 4: Descriptive analysis of socio-demographic and risk characteristics on HCV**  
 520 **screening results**

Characteristics	HCV positive (n=212, %)	HCV negative (n=817, %)	p-value
<b>Age groups</b>			<0.001
16-24 years	40 (18.9)	340 (41.6)	
25-50 years	164 (77.4)	475 (58.2)	
Above 50 years	8 (3.8)	2 (0.2)	

<b>Gender</b>			0.111
Men	200 (94.3)	743 (90.9)	
Women	12 (5.7)	74 (9.1)	
<b>Marital status</b>			<0.001
Unmarried	88 (41.5)	572 (70.0)	
Married	121 (57.1)	239 (29.3)	
Divorced/separated	3 (1.4)	6 (0.7)	
<b>Mean (SD) schooling years (n=1005)</b>	8.9 (2.7)	10.1 (2.2)	<0.001
<b>Needle Sharing</b>			0.014
Yes	123 (58.0)	397 (48.6)	
No	89 (42.0)	420 (51.4)	
<b>Shared a cooker/vial/container</b>			0.009
Yes	79 (37.3)	229 (28.0)	
No	133 (62.7)	588 (71.9)	
<b>Reused needle/syringe</b>			<0.001
Yes	183 (86.2)	589 (72.1)	
No	29 (13.7)	228 (27.9)	
<b>Sexual contact with person with HIV unknown status (yes)</b>			0.002
Yes	64 (30.2)	165 (20.3)	
No	148 (69.8)	647 (79.7)	
<b>Condom use</b>			0.001
No	44 (20.9)	162 (19.6)	
Always	79 (37.4)	413 (50.6)	
Sometimes	88 (41.7)	241 (29.5)	
<b>Tattoo done</b>			0.001
No	69 (32.6)	374 (45.8)	
Yes	143 (67.5)	443 (54.2)	
<b>Weekly alcohol consumption</b>			0.024
No	51 (24.0)	262 (32.1)	
Yes	161 (75.9)	555 (67.9)	

521 **Table 5: Descriptive analysis of risk behavior and prevention exposure with HCV**  
 522 **screening result**

Characteristics	HCV positive (n, %)	HCV Negative (n, %)	p-value
<b>Participated in peer education/IRW intervention</b>			0.869
No	97 (45.8)	379 (46.4)	
Yes	115 (54.3)	438 (53.6)	
<b>Started OST</b>			<0.001
No	114 (53.8)	625 (76.6)	
Yes	98 (46.2)	191 (23.4)	
<b>Attended rehabilitation center</b>			<0.001
No	50 (23.6)	329 (40.3)	
Yes	162 (76.4)	488 (59.7)	
<b>Participated in</b>			0.024

<b>needle/syringe exchange program</b>			
No	51 (24.1)	262 (32.1)	
Yes	161 (75.9)	555 (67.9)	

523 **Table 6: Multivariate analysis of injecting risk behavior, prevention exposure with HCV**  
 524 **screening results**

Characteristics	Adjusted odds Ratio <sup>1</sup>	95% CI	p-value
Needle sharing	1.83	1.27, 2.64	0.001
Reused syringe/needle	2.26	1.34, 3.79	0.002
OST started	1.88	1.26, 2.80	0.002
Attended Rehabilitation Center	1.66	1.10, 2.53	0.017
Participated needle syringe exchange program	0.67	0.42, 1.08	0.108
Tattooing	1.18	0.76, 1.82	0.455
Age	1.10	1.05, 1.22	<0.001
Sex (male)	0.52	0.25, 1.11	0.093
Marital status (married)	0.84	0.55, 1.22	0.427
Educational level	0.79	0.73, 0.85	<0.001

525 <sup>1</sup>Adjusted for age, sex, marital, education level, tattooing, participated in needle syringe exchange program,  
 526 needle sharing, need syringe/needle, OST started, attended rehabilitation center

527



1

STEP 1

**SATELLITE SITES**

(Hotspots, Needle /Syringe Exchange Sites, outreach, Drop In Centers, OST Sites, ART clinics, Rehabilitation Centers)

**RAPID TEST FOR HIV and HIVST**

**RAPID TEST FOR HCV**

**HIV Reactive result**

**HIV non-reactive result**

**HCV Antibody -ve**

**HCV Antibody +ve**

Recommend repeat testing if ongoing risk and link to Education Intervention

**Demonstration Sites (Confirmatory Test for HIV and Blood sample collection for HCV confirmatory Test)**

**HIV 3 test +ve**

**HIV 3 test -ve**

**HCV RNA test Positive**

**HCV RNA test Negative**

Enroll in ART

If Co-infected Link to Treatment (DAA) to National Program

If Mono infected refer for education intervention and link to liver disease assessment

Post Test Counseling

2

STEP 2